Fed in Holding Pattern on Interest Rates, December Cut Possible
Bloomberg Businessweek
Analyzing Eli Lilly's Performance and Market Competition
The chapter delves into investor concerns over Zepbana shortages at Lilly, discussing the company's reassurance of meeting demand. It focuses on Lilly's key drugs like Monjura and Zepbound, evaluating their impact on the company's revenue and supply chain challenges. Additionally, it explores the competitive landscape with companies like Boringa Al-Golheim and Amgen, shifting industry dynamics from COVID to areas such as weight loss, heart disease, and mental health.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
